What would a merger with, or aquisition of MedReleaf bring to Aurora?
(note: all comments in italics are snippets from recent MedReleaf Press Releases)
1. A strong presence in Ontario, with MedRelefeaf's recent purchase of a 1M sq ft greenhouse facility, as well as the current ongoing expansion of the Brandtford facility. That purchase includes adjacent land that would allow a future doubling of the current greenhouse space.
MARKHAM, ON, April 12, 2018 /CNW/ - MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the "Company"), Canada's first and only ISO 9001 and ICH-GMP certified cannabis producer, today announced that it has closed its previously announced agreement to acquire 1 million square feet of existing greenhouse infrastructure on a 69 acre property in Exeter, Ontario ("Exeter Facility") and 95 acres of adjacent land. The total purchase price for the transaction is approximately $26 million, consisting of $21.5 million in cash and 225,083 common shares of MedReleaf.
2. A match with Aurora Larssen Projects to complete the conversion of the recent greenhouse purchase.
Work to retrofit the Exeter Facility for cannabis production will begin in April with first harvest expected in the first quarter of 2019, subject to receipt of a licence from Health Canada. MedReleaf is fully funded to complete the project with cash on hand. The Exeter Facility, after full retrofit, will have annual production capacity of up to 105,000 kilograms, increasing MedReleaf's fully funded annual production capacity to 140,000 kilograms.
3. Guaranteed sales in Quebec, above and beyond the current Aurora agreement
MARKHAM, ON, April 11, 2018 /CNW/ - MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the "Company"), Canada's first and only ISO 9001 and ICH-GMP certified cannabis producer, today announced that it has completed a supply agreement with Société des alcools du Québec ("SAQ") to supply the future Société québécoise du cannabis (SQDC) with high quality adult recreational-use cannabis products in accordance with the previously announced Letter of Intent ("LOI").
Under the terms of the agreement, MedReleaf is committed to supplying the Quebec market with 8,000 kilograms of cannabis products per year with a minimum three-year term.
4. Expanded presence in Germany and Australia
MARKHAM, ON, March 19, 2018 /CNW/ - MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the "Company"), Canada's first and only ISO 9001 and ICH-GMP certified cannabis producer, today announced that it has entered into an agreement to become the largest supplier of medical cannabis products to Cannamedical Pharma GMBH ("Cannamedical"), a leading medical cannabis distributor to pharmacies in Germany. MedReleaf will provide Cannamedical with monthly exports of five of its premium strain varieties significantly improving the predictability and security of drug delivery to the German market. Sales to Germany will commence promptly upon the expected receipt of MedReleaf's European Medical Agency Good Manufacturing Practices ("GMP") certification and export permit from Health Canada in the coming weeks.
MARKHAM, ON, Nov. 14, 2017 /CNW/ - MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the "Company"), Canada's first and only ISO 9001 and ICH-GMP certified producer of medical cannabis, today announced that its Australian joint venture partner, Indica Industries Pty Ltd. (t/a "MedReleaf Australia"), has been granted a licence from the Australian Government Office of Drug Control ("ODC") for the cultivation and production of medical cannabis. The licence to undertake authorized cannabis activities commences on November 10, 2018 in order to allow time to complete infrastructure development of the facility.
5. Expanded Medical product lines
MARKHAM, ON, Feb. 6, 2018 /CNW/ - MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the "Company"), Canada's first and only ISO 9001 and ICH-GMP certified cannabis producer, today announced that it has received Health Canada approval for the sale of its cannabis oil softgel capsules, becoming the first licensed producer ("LP") to bring colour-coded and cannabis variety-specific softgel capsules to market and the only LP to manufacture softgel capsules from a certified ISO and GMP facility.
"Orally ingested softgel capsules give prescribing physicians and patients precise dosing in a familiar and convenient medicinal form factor. These products provide access to cannabis for an under-served patient community more comfortable taking their medication in a traditional capsule rather than by oil or through vapourizers," said Robert Gora, Senior Director of Physician Outreach. "As part of MedReleaf's ongoing focus on patient safety, our softgel capsules are uniquely colour-coded to allow patients to easily differentiate between the specific cultivar or type of oil product that they are consuming, letting patients more safely manage their medication."
6. Expanded premium brand line-up
MARKHAM, ON, April 3, 2018 /CNW/ - MedReleaf Corp. (TSX:LEAF) Canada's first and only ISO 9001 and ICH-GMP certified cannabis producer, today announced the introduction of AltaVie by MedReleaf, the Company's premium recreational cannabis brand designed for a premium consumer who is curious, discerning about life in general and searching for physical, mental and emotional enrichment.
MARKHAM, ON, March 6, 2018 /CNW/ - MedReleaf Corp. (TSX:LEAF), Canada's first and only ISO 9001 and ICH-GMP certified cannabis producer, today announced it has entered into an exclusive licencing agreement with Woodstock Cannabis Company for use of the iconic Woodstock brand in the Canadian cannabis market.
This is not a complete summary of MedReleaf. For further information, I recommend visiting their Investors page links, which can be found on their main website.
